That drug pricing bill passed. Now what?
Yesterday, the House passed a bill that would cut consumer drug spending by 55% and cost the biopharma industry about $1 trillion in revenue over a decade. No one expects it to get traction in the Senate, and President Trump has promised a veto even if it did. But that doesn’t make this meaningless.
As STAT’s Lev Facher reports, the bill sets the agenda for Democrats in what is likely to be a long fight over drug prices. There’s bipartisan concern over the rising cost of medicine, and the House bill, however doomed, could serve as a stake in the ground for future negotiations.
Then there’s the upcoming election. Democrats are hoping to seize control of the White House and Senate in 2020, and the House pricing bill could double as a campaign pitch and blueprint for future legislation.
Read more.
As STAT’s Lev Facher reports, the bill sets the agenda for Democrats in what is likely to be a long fight over drug prices. There’s bipartisan concern over the rising cost of medicine, and the House bill, however doomed, could serve as a stake in the ground for future negotiations.
Then there’s the upcoming election. Democrats are hoping to seize control of the White House and Senate in 2020, and the House pricing bill could double as a campaign pitch and blueprint for future legislation.
Read more.
No hay comentarios:
Publicar un comentario